Entrada Therapeutics
TRDA
111 hedge funds and large institutions have $290M invested in Entrada Therapeutics in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 28 increasing their positions, 43 reducing their positions, and 11 closing their positions.
490% more call options, than puts
Call options by funds: $124K | Put options by funds: $21K
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
8% more funds holding
Funds holding: 103 → 111 (+8)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1.47% less ownership
Funds ownership: 86.52% → 85.06% (-1.5%)
35% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 43
48% less capital invested
Capital invested by funds: $560M → $290M (-$270M)
Top Buyers
Top Sellers
TRDA Hedge Fund Activity: Q1 2025 in Review
111 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q1 2025, worth a combined $290M — down 48% from $560M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new TRDA positions and 11 closed out — a net gain of 8 holders — while 28 added to existing stakes and 43 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $2.02M. The largest seller was Goldman Sachs, cutting an estimated $2.4M.
- 111 institutional investors held Entrada Therapeutics (TRDA) as of Q1 2025, up from 103 in Q4 2024.
- Funds reported $290M of Entrada Therapeutics stock for Q1 2025, down 48% quarter-over-quarter.
- 19 funds opened new Entrada Therapeutics positions in Q1 2025 and 11 closed out, a net change of +8 holders.
- The largest Entrada Therapeutics buyer in Q1 2025 was Renaissance Technologies, an estimated $2.02M added.
- The largest Entrada Therapeutics seller in Q1 2025 was Goldman Sachs, an estimated $2.4M sold.
Based on aggregated 13F filings for Q1 2025.